Nezastomig
Nonpapillary Renal Cell Carcinoma
Explore 112 assets in Nonpapillary Renal Cell Carcinoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Regeneron Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03972657CT.gov A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nezastomig (this asset) | Regeneron Pharmaceuticals | P1/2 | CC · 45 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
| Irinotecan | M.D. Anderson Cancer Center | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Nezastomig
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P1/2 | CC · 45 |
| Castration-Resistant Prostate Carcinoma | — | P1/2 | CC · 43 |
| Metastatic Prostate Carcinoma | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- NivolumabFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Nezastomig in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nezastomig-nonpapillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →